You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 6,225,340

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,225,340

Title:	Angiogenesis inhibitor for the treatment of endothelial cell proliferation
Abstract:	The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Inventor(s):	Wuthier; Roy E. (Columbia, SC), Nie; Daotai (Detroit, MI)
Assignee:	University of South Carolina (Columbia, SC)
Application Number:	09/281,577
Patent Claims:	1. A method for inhibiting arthritis sensitive to a composition as listed below in a patient, comprising administering to said patient a therapeutically active dosage of said composition comprising 5-amino-2,2-dimethyl-6-[3'-(R,S) amino-4'-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one, wherein said composition is administered via a pharmaceutically or veterinarily acceptable carrier for a time effective to inhibit arthritis in said patient. 2. The method as in claim 1, wherein said therapeutically active dosage is in the range of about 0.2 .mu.g per kilogram of body weight per minute to about 200 g per kilogram of body weight per minute. 3. The method as in claim 1, wherein said composition is administered via a mucosal route. 4. The method as in claim 1, wherein said composition is administered via a parenteral route. 5. The method as in claim 1, wherein said pharmaceutically or veterinarily acceptable carrier is chosen from the group consisting of saline, glucose, sterile water and mixtures thereof. 6. A method as in claim 1, wherein said composition further comprises an auxiliary substance, such auxiliary substance selected from the group consisting of adjuvants, buffers, flavoring agents, viscosity enhancers, preservatives and mixtures thereof. 7. A method as in claim 6, wherein said adjuvant is selected from the group consisting of aluminum hydroxide, muramyl dipeptide, lipopolysaccharide and mixtures thereof.

Details for Patent 6,225,340

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2017-11-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.